<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">46450</article-id><article-id pub-id-type="doi">10.7554/eLife.46450</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-25647"><name><surname>Csanády</surname><given-names>László</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6547-5889</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-58609"><name><surname>Töröcsik</surname><given-names>Beáta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Medical Biochemistry</institution>, <institution>Semmelweis University</institution>, <addr-line><named-content content-type="city">Budapest</named-content></addr-line>, <country>Hungary</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-34456"><name><surname>Islas</surname><given-names>Leon D</given-names></name><role>Reviewing editor</role><aff><institution>Universidad Nacional Autónoma de México</institution>, <country>Mexico</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>csanady.laszlo@med.semmelweis-univ.hu</email> (LC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>06</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e46450</elocation-id><history><date date-type="received"><day>27</day><month>02</month><year>2019</year></date><date date-type="accepted"><day>14</day><month>06</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Csanády &amp; Töröcsik</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Csanády &amp; Töröcsik</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-46450-v1.pdf"/><abstract><p>The devastating inherited disease cystic fibrosis (CF) is caused by mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) anion channel. The recent approval of the CFTR potentiator drug ivacaftor (Vx-770) for the treatment of CF patients has marked the advent of causative CF therapy. Currently, thousands of patients are being treated with the drug, and its molecular mechanism of action is under intensive investigation. Here we determine the solubility profile and true stimulatory potency of Vx-770 towards wild-type (WT) and mutant human CFTR channels in cell-free patches of membrane. We find that its aqueous solubility is ~200-fold lower (~60 nanomolar), whereas the potency of its stimulatory effect is &gt;100-fold higher, than reported, and is unexpectedly fully reversible. Strong, but greatly delayed, channel activation by picomolar Vx-770 identifies multiple sequential slow steps in the activation pathway. These findings provide solid guidelines for the design of <italic>in vitro</italic> studies using Vx-770.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Xenopus</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000897</institution-id><institution>Cystic Fibrosis Foundation</institution></institution-wrap></funding-source><award-id>CSANAD17G0</award-id><principal-award-recipient><name><surname>Csanády</surname><given-names>László</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003825</institution-id><institution>Magyar Tudományos Akadémia</institution></institution-wrap></funding-source><award-id>Lend&amp;#x00FC;let grant LP2017-14/2017</award-id><principal-award-recipient><name><surname>Csanády</surname><given-names>László</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>László Csanády, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of Semmelweis University (last approved 06-30-2016, expiration 06-30-2021).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript or can be visualized in the figures.</p></sec><supplementary-material><ext-link xlink:href="elife-46450-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>